![](/images/graphics-bg.png)
Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients
المؤلفون المشاركون
Bashir, Salah O.
Umar, Haydar A.
Aamir, Mahmud A.
Sumali, Rashid
Mursi, Muhammad D.
المصدر
Saudi Journal of Kidney Diseases and Transplantation
العدد
المجلد 26، العدد 6 (31 ديسمبر/كانون الأول 2015)، ص ص. 1135-1141، 7ص.
الناشر
تاريخ النشر
2015-12-31
دولة النشر
السعودية
عدد الصفحات
7
التخصصات الرئيسية
الموضوعات
الملخص EN
Secondary hyperparathyroidism is almost a constant feature in chronic kidney disease (CKD) patients maintained on hemodialysis (HD).
Calcimimetic agents appear to offer an alternative to surgery in controlling secondary hyperparathyroidism in these patients.
Recent studies provide conflicting data on the benefits, efficacy and tolerance of cinacalcet as first-line therapy for the treatment of secondary hyperparathyroidism in CKD.
This study was designed to investigate the efficacy and tolerance of a low dose of the calcimimetic agent cinacalcet in patients on long-term HD having moderate to severe secondary hyperparathyroidism.
Twentyfive adult male patients on HD for more than three years were included in the study.
All had moderate to severe secondary hyperparathyroidism with serum intact parathyroid hormone (iPTH) >50 pmol/L, resistant to conventional treatment.
We used the targets of Chronic Kidney Disease: Outcomes Quality Initiative (K/DOQI) clinical guidelines as optimal target of serum iPTH, calcium and phosphate.
Patients were administered cinacalcet as a single oral daily dose of 30 mg and were followed-up for six months.
Cinacalcet treatment for six months resulted in a significant reduction in the serum phosphate and iPTH levels while the serum calcium levels remained unchanged.
Thirty-six percent of the patients attained the recommended serum iPTH levels, 40% achieved significant reduction of the serum iPTH levels and 24% showed no favorable response.
Only one patient dropped out because of severe gastrointestinal symptoms.
Our results suggest that treatment of CKD patients, having moderate to severe secondary hyperparathyroidism, with low-dose cinacalcet is effective and well tolerated.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Bashir, Salah O.& Umar, Haydar A.& Aamir, Mahmud A.& Sumali, Rashid& Mursi, Muhammad D.. 2015. Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation،Vol. 26, no. 6, pp.1135-1141.
https://search.emarefa.net/detail/BIM-629570
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Bashir, Salah O.…[et al.]. Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation Vol. 26, no. 6 (Nov. / Dec. 2015), pp.1135-1141.
https://search.emarefa.net/detail/BIM-629570
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Bashir, Salah O.& Umar, Haydar A.& Aamir, Mahmud A.& Sumali, Rashid& Mursi, Muhammad D.. Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation. 2015. Vol. 26, no. 6, pp.1135-1141.
https://search.emarefa.net/detail/BIM-629570
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 1140-1141
رقم السجل
BIM-629570
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)